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Abstract
Raman spectroscopy is an optical technique that allows for label-free biological
investigations to take place. This thesis confronts two biological cases: dopamine (DA) detection
at physiological levels and assessment of renal osteodystrophy (ROD). We employed surfaceenhanced Raman spectroscopy recording DA concentrations as low as 10−11 molar. Quantum
chemical density functional calculations were carried out using Gaussian. Agreement between the
simulated and experimentally determined results indicates the existence of distinct DA molecular
forms, such as DA±, DA−, and dopaminequinone. Disappearance of the strongest bands of
dopamine suggests its adsorption onto the metallic surface. On the other hand, occurrence of the
above-mentioned Raman lines indicates DA multi-layer formation or a cationic DA+ form. These
insights allow for a better understanding of its detection at physiological levels, which is crucial if
a further optovoltammetric medical device development is envisioned. ROD requires a different
approach, due to difficulties in defining the pathogenesis and treatment efficacy, since there are
many factors that affect bone quality. We used confocal Raman microscopy and parallel statistical
analysis to identify differences in bone composition between healthy and ROD bone tissues. Three
main compositional parametric ratios are directly visualized: calcium content, mineral-to-matrix,
and carbonate-to-matrix. An accumulation of phenylalanine is Raman spectroscopically observed
for the first time in ROD samples. Image results are based on tens of thousands of spectra per
sample leading to a powerful means in distinguishing between the two types of samples. The
statistical outcomes demonstrate that only a relatively small number of spectra need to be recorded
to classify the samples. This work opens the possibility of future development of in vivo Raman
sensors for assessment of bone structure, remodeling, and mineralization, where various
biomarkers are simultaneously detected with unprecedented accuracy.
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Chapter 1: Introduction

1.1 Introductory Remarks
Raman spectroscopy is an optical technique focusing on inelastic scattering – an event that
was first predicted in 1923 by Adolf Smekal [1]. Shortly after Smekal’s hypothesis, the inelastic
scattering event was independently discovered by two Indian scientists in 1928 [2]. These two
scientists created the foundation of Raman spectroscopy. Sir Chandrasekhara Venkata Raman and
his student, Sir Kariamanickam Srinivasa Krishnan, identified the inelastic scattering effect
through observing purified liquids. Sir Raman acknowledged the existence of elastic scattering,
known as secondary radiation, as per the successful investigations conducted by Sir George Stokes
[2]. Questions arose to Sir Raman as secondary radiation could not apply to all-natural phenomena
– the scattering of light causing the colours of the sky or giving deep ocean water the colour blue.
When experimenting with purified, clear, and transparent liquid media, Sir Raman noticed colour
shifts that would occur. Within purified toluene, the light emitted from a lantern would become a
bright blue, no matter the purity within the solution. Sir Raman also observed this shift from orange
to blue light in clear blocks of ice and optical glass[2]. Sir Raman and his student investigated a
multitude of liquids, all of which exhibited various degrees of this scattering effect. It was then
when they achieved a phenomenal observation of the effect in pure dry glycerin. The “new
radiation” was what Sir Raman announced, following their investigations in pure dry glycerin.
This was also the point where Raman scattering was discovered officially for the first time. It was
the period when a new spectroscopic technique – a technique whose potential later on would be
considered limitless – was coming alive into the research community.
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The fundamental spectroscopic method that will be used in this thesis for investigating
different biological materials will be Raman spectroscopy. The phenomenon of wavelength
modification following scattering is known as inelastic scattering – an event that occurs only in
about one out of ten to twenty million photons within a natural setting. If this wavelength
difference occurs because energy is transferred towards the material, i.e. the material absorbs a
small subset of energy from the photon, then Stokes Raman scattering occurs. In rarer events, the
opposite transpires. The material gives off energy, and the photon absorbs it instead. This opposite
event is known as anti-Stokes Raman scattering. Outside of the realm of inelastic scattering, elastic
scattering takes precedence, being the majority of light scattering that occurs. While elastic
scattering can refer to a multitude of different areas, such as a kinetic collision between objects, it
is normally referred by a different terminology when only light is being considered. We call this
terminology Rayleigh scattering, which occurs only when there is no modification of the
wavelength following the scattering. It is these different methods of light scattering, primary that
of inelastic scattering, that serve as the foundations of Raman spectroscopy.
This thesis will be focused on the label-free application, observation, and analysis of
Raman spectroscopy on biological investigations. Two distinct focuses will be present: the
neurotransmitter dopamine and renal osteodystrophy. The applications and extension of Raman
spectroscopy are uncountable, especially considering its potential towards biomedical
applications. Raman spectroscopy is currently being investigated towards neurochemical
approaches as an alternative for existing diagnostic techniques. Leveraging the label-free
advantages Raman spectroscopy has to offer, together with its high spatial and temporal resolution,
presents a novel approach that has the potential to revolutionize neurochemical investigations of
the future. Within the realm of renal osteodystrophy, Raman spectroscopy applications can provide
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nearly the same information as traditional transiliac bone biopsies, without encompassing the same
degree of invasiveness. Furthermore, the generation of visualization techniques adds a unique
perspective towards tackling the disease; rapid acquisition and localization of signatures may bring
more insights than a simple analysis alone. The following sections within this chapter will further
elucidate the problems and challenges that exist in both dopamine and renal osteodystrophy
research, and how Raman spectroscopy may provide an answer and solutions for their accurate
detection.

1.2 The Neurotransmitter Dopamine
Dopamine’s function as a neurotransmitter was discovered over sixty years ago, and since
then it has become one of the most studied neurotransmitters [3]. Within the central nervous system
(CNS), neurons releases dopamine as a signaling agent for inter-neuronal communication.
Depending on the region and application, dopamine can act as either a neurotransmitter or
neuromodulator. Dopamine’s influence on the central nervous system affects many roles and
pathways, among which are upper cognitive function, motivation, motor control, reinforcement,
arousal, reward, sexual gratification, nausea, addiction, and lactation [4]–[6]. Outside of the central
nervous system, dopamine is involved with cardiac, renal, gastrointestinal, and immune systems
where it acts as a potent receptor antagonist [7]–[12]. Despite dopamine’s unique and far-reaching
effects, dopamine is regulated by mechanisms common to all monoamine neurotransmitters, as
well as having an involvement in similar synthesis pathways.
The majority of dopamine synthesis follows a series of enzymatic reactions originating
from the essential amino acid, phenylalanine. The first synthesis step involves the conversion of
phenylalanine into tyrosine by phenylalanine hydroxylase, located both in the kidney and in the
liver. At this stage, tyrosine can be used in the synthesis for all catecholamines, depending on the
3

enzyme acting upon it. In the case of dopamine, tyrosine is absorbed into the central nervous
system through low-affinity amino acid transports, and, afterwards, by high-affinity amino acid
transports present on dopaminergic neurons [13]. Within the dopaminergic neurons, tyrosine is
converted into the dopamine precursor, dihydroxyphenylalanine (L-DOPA), through tyrosine
hydroxylase. Whilst only one enzymatic step separates L-DOPA from dopamine, the physical
properties are deviant enough to enable different transportation pathways. For instance, L-DOPA
can cross the blood-brain barrier, whereas dopamine cannot do so. This property of L-DOPA
makes it attractive for pharmaceutical and treatment approaches, leading to the popularity of using
L-DOPA for dopamine-related diseases rather than the neurotransmitter itself. L-DOPA is
converted to dopamine in dopaminergic cells through aromatic L-amino acid decarboxylase, where
dopamine is kept into storage until the body requests it.
Diagnostic approaches can take advantage of where the brain stores dopamine. There are
two primary regions in the brain where dopamine-producing neurons are present: the ventral
tegmental area (VTA) and the substantia nigra (SN) [14]. The VTA is associated with the reward
pathway where dopamine released from the VTA enters the nucleus accumbens and the prefrontal
cortex. The SN is focused with the motor pathway, releasing dopamine into the dorsal striatum
instead. When dopamine is stored in specialized synaptic vesicles, dopamine concentration can
reach significant levels – approximately 0.1 M [13]. The combination of having only a few
locations in the CNS containing dopamine-producing neurons, together with the high
concentration of the neurotransmitter at these locations, presents itself as an attractive and
accessible diagnostic target.

4

1.3 DOPAMINE SPECTROSCOPY LITERATURE
Early neurotransmitter studies noted several advantages of Raman spectroscopy over other
diagnostic techniques, paving way towards Raman spectroscopic diagnostic approaches used
today. Perfusion methods were some of the most used techniques in monitoring the extracellular
concentration of various neurotransmitters. Following extraction from the brain, electrochemical
detection, such as the usage of voltammetry, and chromatography were applied to measure the
concentrations of neurotransmitters within the sample [15]–[18]. However, there were distinct
complications that impeded the efficacy of these techniques regarding dopamine itself.
An interference plagued voltammetry results due to the oxidation potential of several
metabolites in the CNS, as seen with ascorbate, dihydroxyphenylacetic acid (DOPAC), and uric
acid. Since ascorbate has a lower anodic potential than dopamine, measurements contained both
ascorbate and dopamine readings once the electrode reached dopamine potential levels [15], [16].
Furthermore, the basal concentration of ascorbate is higher than dopamine, resulting in further
interference (more than the base potential differences themselves) [17]. It was noted that at the
physiological pH of 7.4, ascorbate and dopamine exist in two different charged forms [16], [17].
Ascorbate would be in an anionic form (pKa = 4.10), whereas dopamine would be in a cationic
form (pKa = 8.87) [16], [17], [19]. This observation allowed for the generation of chemically
modified electrodes, with Nafion or stearate, repelling negatively charged ascorbate and improving
dopamine selectivity [15]–[17], [19]. This approach also repelled other negatively charged species,
such as uric acid. Yet the complication of several metabolites having overlapping oxidation
potentials induced unavoidable interferences within voltammetry measurements [17], [20], [21].
Liquid chromatography (LC), while avoiding all the complications affecting voltammetry,
was receptive to a new, distinct issue – the real-time response. The application of LC on CNS
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tissue allowed for the distinction of not only dopamine but also of other various species, including
serotonin, norepinephrine, epinephrine, and related metabolites [18], [22], [23]. The unfortunate
drawback of the procedure was the time, with an average measurement time was in the realm of
fifteen to twenty minutes [15], [18], [22], [23]. This prolong measurement duration introduced
complications of its own, such as the inevitable oxidation of the analytes themselves.
Catecholamines are subject to oxidative breakdown, which necessitates the addition of antioxidants to the dialysates used in the assays [18], [22], [23]. Approaches have been taken to reduce
the time required for the measurements to be conducted, but inevitable drawbacks occured. The
assays were restricted regarding which analytes may be measured, focusing only on a single
analyte and its metabolites. However, the duration of assays were lowered to approximately fifteen
minutes for completion, allowing for more samples to be analyzed within the same time period of
traditional approaches [22], [24].
Thus, considering the traditional methods for measuring neurotransmitters, new
approaches that would avoid the interference of various analytes, as well as being performed within
an appreciable time period, were highly sought for. Raman spectroscopy emerged as a promising
technique that could achieve the desired results in neurochemical investigations [15]. Considering
the in vivo concentration of dopamine release, especially on a single-cell level, high spatial
resolution was desired [25]. Not only was spatial resolution required, but temporal resolution as
well, considering that the average duration of vesicle release is occurring within a few milliseconds
[26]–[28]. In this context, it is important to note that extracellular concentration of dopamine can
linger following exocytosis up to a few seconds, allowing leniency in some temporal
measurements [27]. Raman spectroscopy can achieve these high temporal and spatial resolution
criteria critical for in vivo analysis of neurotransmitters.
6

Previous studies of observing catecholines through Raman spectroscopy have been
conducted though some limitations and constraints have been noted. For example, early studies of
catecholines showed significant complications regarding detection sensitivity. The desired
physiological sensitivity of ~10-6 M was difficult to achieve through spontaneous Raman
spectroscopy [15]. However, with the application of resonant and surface enhancement, the desired
physiological limit was achievable [15]. The usage of metallic nanoparticles significantly
increased the spatial resolution, past the physiological threshold. Measurements within the
nanomolar and picomolar range were possible [29], [30].
The early 2000s herald the advancement of Raman spectroscopy in tackling
neurotransmitters, with dopamine being no exception. Vibrational spectroscopy allows for the
unique identification of neurotransmitter as well as for the discrimination between species and
their derivatives. However, the need for an apparatus to make Raman spectroscopy viable for in
vivo studies became apparent. Electrochemical techniques, such as cyclic voltammetry, used
electrodes for their probing, taking advantage of the oxidative nature of catecholamines in such
measurements [15]–[17], [19], [31]. In contrast, optical spectroscopy requires sensors that carry
signals through optical means, not electrochemical. Optical sensors became an attractive approach
as a suitable probe for Raman spectroscopy, with several studies revealing the efficacy of such
probes [31]–[36]. In regards towards catecholamines, the technology portrayed a moderate
success, which varied based on the SERS substrate utilized [31]. Dopamine detection was
achievable at the micromolar range through optical fibers while using relatively low laser power
and preserving rapid signal acquisition times [31].
Advances in surface-enhanced Raman spectroscopy opened new avenues in approaching
catecholamine detection. Not only was dopamine detection possible, but monitoring the release
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and secretion of dopamine was achieved [25]. Using a silver nanoparticle substrate, catecholamine
secretion was observed for the first time and simultaneously allowed for identity of the secreted
neurotransmitters [25]. However, temporal issues were encountered when scanning a group of cells
– each cell took approximately 10 minutes for a Raman mapping to complete. However,
conducting static measurements within a focused region can successfully record the desired
catecholamine spectra [25], [29].
Recent advances in substrate fabrication and distribution of SERS have brought a massive
leap forward in the reliable detection of dopamine at in vivo concentrations. Single-molecule
detection was achieved for the first time with silver nanoparticles as SERS substrate [37], paving
way towards physiological detection of dopamine. Through meticulous silver substrate fabrication,
molecules of interest could be analyzed within appropriate locations on the substrate. This
statement reveals two characteristics of the SERS substrate: high sensitivity and the requirement
of “hot-spot” locations [37]. It has been demonstrated that the high sensitivity is definitely
possible. However, the complication of having dopamine molecules within range of the random
“hot-spot” colloidal clusters became a bottleneck issue. Although, continuous refinement of SERS
nanoparticles have improved the probability of “hot-spots” occurring, the bottleneck issue still
continues to be present [38]–[40]. Despite the reliance of “hot-spot” interaction between analytes
of interest and the SERS substrate being required, the massive increase in detection sensitivity is
well worth the tradeoff. Currently, the limit of detection for dopamine using SERS reaches the
minimal dopamine in vivo concentrations; nanomolar and sub-nanomolar concentrations
compared to physiological limits between 10 and 100 nanomolar [41], [42].
The current questions arising on dopamine detection with SERS rely on increasing the
“hot-spot” effect, affecting both the occurrence and reliability of the phenomenon. Certain
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vibrations, and therefore locations on a molecule are receptive to the phenomenon. Therefore, the
question regarding the interaction between the molecule and the SERS substrate is brought to the
foreground. Further understanding of this interaction can lead to prediction and reliable occurrence
of this effect. Not only can chronic in vivo dopamine monitoring be achieved but also the
understanding of catecholamine dynamics within the local environment can be established. The
success of these two goals will inevitable lead towards a reliable, and powerful means of
neurotransmitter monitoring in the future.
1.4 RENAL OSTEODYSTROPHY
Chronic kidney disease (CKD) is a globally present disease, affecting nearly 10% of the
adult population that have some CKD variation [43]. As the kidney fails, there is a progressive
disruption of mineral and waste homeostasis within the body. Chief importance is the kidney’s
influence on circulatory levels of phosphate and calcium. With the deterioration of the kidney’s
ability to filter, increased concentration of serum phosphate is observed. Excess serum phosphate
binds with available calcium, and being a non-homeostatic event, the serum concentration of
calcium decreases. In response, the parathyroid glands release parathyroid hormones (PTH) to
increase serum calcium levels towards normal homeostasis levels. In CKD, the kidney cannot
respond to PTH correctly, due to impairment of the kidney’s ability in converting 25hydroxyvitamin D (abbreviation 25(OH)D and also known as the prehormone, calcifediol) to the
hormonally active metabolite 1,25-dihydroxycholecalciferol, known as calcitriol. Calcitriol serves
as the primary response to PTH, by increasing serum calcium levels through stimulating calcium
uptake from the intestines. However, in kidney dysfunction, the synthesis of calcitriol is severely
impacted, leading to a disruption of the calcium uptake from the intestines. In this situation, the
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skeletal system is targeted as a large calcium reservoir backup, which serves as the entrance
towards renal osteodystrophy (ROD).
The bone is not a stagnant tissue model, but a dynamic one. There is a constant remodeling
process occurs throughout the bone’s lifespan. This remodeling process is known as burn turnover,
which comprises two primary processes working together: bone formation and bone resorption.
Dynamic equilibrium is enacted once the bone has achieved its peak mass for its structure [44].
During this metabolic event, a variety of different molecules are released into the local circulation
that are identified as bone turnover markers (BTM) [45]. Markers for bone formation include
osteoclacin (matrix protein), procollagen Type I propeptides (C-terminal: PICP, N-terminal:
PINP), and osteoblast enzymes including serum alkaline phosphatase (ALP) [44]. The bone
resorption process includes more markers which encompass the collagen degradation products,
noncollagenous proteins, osteoclastic enzymes and osteocyte activity markers [44]. In healthy
bone tissue, standard bone resorption takes place over the course of 10 days, with bone formation
requiring approximately 3 months for completion [44], [46]. On a per-year basis, up the 20% of
the human skeleton may fully undergo bone turnover, being completely replaced in the process
[46].
Renal osteodystrophy is an exclusive measurement of bone morphological changes in strict
relationship with CKD [47]. ROD manifests itself with abnormalities in the bone turnover rate,
which has been detailed in depth and has been linked as a factor of bone quality [48], [49]. Both
low- and high-turnover rates within ROD result in abnormalities that negatively affect a patient’s
outcome, with a serious influence on bone fracture incidence [49], [50]. Depending on the rate of
turnover, BTM varies over a significant range, providing an interesting perspective of the bone’s
remodeling process. In low-rate turnover, cancellous bone volume and trabecular bone thickness
10

were lower than those of normal-rate turnover, whereas high-rate turnover exhibited an opposite
trend, with increases in volume and thickness [49]. When looking at certain BTM ratios (which is
a part of bone quality diagnosis), high-rate turnover exhibits less minerals within the tissue, leading
to reduced mineral-to-matrix ratios. These ratios, as well as a lower carbonate-to-phosphate ratio,
are reduced compared to low-rate turnover [49]. Despite variances in bone turnover occurring in
ROD, bone quality is the primary, and major, indicator if ROD is present. The fundamental
methods of ROD diagnosis and skeletal chronic kidney disease-mineral and bone disorder (CKDMBD) are transiliac bone biopsy and histomorphometry (alongside with its derivatives) [50].
While the nature of these procedures is undoubtably invasive, they nonetheless remain as the “gold
standards” in bone diagnostics. Minimally to non-invasive techniques that provide similar degrees
of diagnostic information are currently being sought for. Specifically, techniques that can provide
in-depth information regarding bone’s quality, progression of ROD by observing BTM, and risk
evaluation of bone fractures. These essential evaluations are the primary areas of focus for these
new techniques.

1.5 BONE AND BONE QUALITY
Healthy bone is a natural inorganic-organic composite, the majority consisting of collagen
followed by bone minerals (biological apatite, primarily hydroxyapatite) serving as the structural
framework. Secondary constituents include proteins, lipids, cells, vascular elements, and
additional trace ions (potassium, sodium, magnesium, chloride, fluoride, citrate, and carbonate)
[51]. From a biomechanical perspective, hydroxyapatite provides toughness and rigidity for the
bone, with collagen assisting in providing tensile strength and flexibility [52], [53]. An important
consideration must be given to all the individual constituents that compose the bone as numerous
and distinct diseases arise from the unhealthy variances in these constituents.
11

The common means of describing the bone health is through the umbrella diagnostic
known as bone quality. This evaluation is derived from both biological and clinical perspectives,
and encompasses all present known bone abnormalities in the following categories: bone turnover,
mineralization, bone volume, linear growth, strength, and vascular and soft tissue calcification
[49], [54]–[57]. While detrimental changes within the bone structure may develop with the early
onset of ROD, these changes worsen significantly with the continuous degradation of the kidney
function. As such, individuals with advanced CKD tend to exhibit more severe forms of ROD.
Other similar diseases resulting in degenerative bone disease include hyperparathyroid-mediated
high-turnover bone disease, osteitis fibrosa cystica, adynamic bone disease, osteomalacia, and
mixed uremic osteodystrophy [49], [57]–[59].
There are several complications with understanding the pathogenesis of ROD and efficacy
of subsequent treatments. The primary means of determining metabolic bone disease status is
through bone quality. There are a wide variety of factors affecting bone quality. Consequently, no
clear distinction between key bone lesions, nor clarity regarding mechanisms of action. Thus, clear
diagnosis becomes a complicated matter [59], [60]. For example, osteomalacia and osteoporosis
are both potential contributors towards ROD and with a courtesy glance, they may be confused for
one another. Deeper analysis reveals that there is a distinction in the bone characteristics between
the two cases. While osteoporosis leads to porous and, therefore, brittle bone, osteomalacia leads
to softening of the bones instead. This variation reveals itself in bone quality, with an association
attributed to the modification in the ratio between mineral and organic material. For example,
osteomalacia exhibits a much more reduced ratio than that in osteoporosis [61]. In the context of
ROD, it is prudent to consider the presence of phenylalanine within the bone tissue. Phenylalanine
hydroxylase is a metabolic enzyme that generates tyrosine from phenylalanine and is located in
12

both the kidney and the liver. With chronic kidney disease, this enzyme is detrimentally affected
and function is deteriorated [62], [63]. This condition secondarily elevates the status of tyrosine to
an essential amino acid as per failure of generating tyrosine from phenylalanine in CKD patients
[63]. With tyrosine being the precursor to dopamine and other catecholamines, severe reduction
of tyrosine could result in decreased dopamine production [64]. The investigation of the
relationship between renal failure and catecholamines is out of scope for this thesis, however it
may be an area of interest for future work. With regard to the incapacitated phenylalanine
hydroxylase, higher concentrations of phenylalanine will be present within the circulatory system.
This singular event leads to the potential deposition of phenylalanine in the bone matrix. Regarding
all the information about phenylalanine, this is but just one constituent of the bone quality umbrella
diagnostic; a new variable that separates ROD bone from normal bone.
Assessing bone quality is commonly conducted with bone histomorphometry, as a means
of diagnosing metabolic bone diseases and derivatives thereof. Bone histomorphometry reveals
bone turnover, mineralization, and volume based on in vitro diagnosis from biochemical markers
(as per sample staining) of transiliac bone biopsies [65], [66]. Unfortunately, the actual execution
of the bone histomorphometry technique is not one of a simple nature. Besides the invasive nature
of the biopsies, bone histomorphometry requires experienced pathologists to both recognize and
classify the above-mentioned abnormalities hidden in the sample. The lack of standardized normal
values leads to a delicate decision process; a challenge that persists in obtaining accurate results
within many laboratories. Whilst bone histomorphometry remains the primary technique for
assessing bone quality, alternative methods that achieve improvements in the reliable assessment
of bone properties is desirable. One appealing alternative is the application of optical spectroscopic
techniques. Considering the reliance of assessing multiple components within bone samples to
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determine bone quality, Raman spectroscopy has the natural ability to reveal the information of all
molecular constituents at once. This spectroscopic technique can be used without the need of any
prior staining, providing a label-free and simultaneous indication of all bio-markers within the
sample. Therefore, it is possible to identify key bone compositional characteristics, such as
mineral-to-matrix ratio, mineral crystallinity, carbonate-to-phosphate ratio, carbonate-phosphate
turnover in the mineral lattice, and quantification of collagen cross-links – parameters that have
been already successfully investigated through other optical techniques as previously reported in
literature [67]–[73]. These studies reveal modifications of bone tissue composition as seen with
impaired bone micro-architecture, leading to increased fracture risk in metabolic bone diseases
[67]–[73]. However, the majority of previous optical studies were based on Fourier-transform
infrared optical spectroscopy (FTIR) [67]–[70]. Only recently have explorations using Raman
spectroscopy been conducted. Thus, such Raman analysis towards metabolic bone diseases still
remains rather scarce in literature [71]–[73].
In the future of optical fibre-based sensors, especially towards ROD diagnosis, Raman
spectroscopy has been considered as a strong contender due to a variety of characteristics that
accompany it. Compared to traditional optical methods, Raman spectroscopy exhibits better spatial
resolution which is a critical component towards in vivo ROD detection. Raman spectroscopy has
been applied towards ex vivo measurements of fresh tissue samples [71]–[73]. Unfortunately, there
is a slight variance in Raman spectra because of the common embedding matrix material used for
bone tissue samples, polymethyl methacrylate [74]. This embedding material is standard in the
preparation for samples used in FTIR and histomorphometrical studies, which leads to a few
complications when it comes to Raman spectroscopy analysis. The embedment can influence the
bone sample through different processes, such as: (1) leaching of minerals from the sample during
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chemical fixation, (2) collagen bond vibration modifications due to interactions with the
embedding material and, (3) potential overlap in signals from the embedding materials and the
sample itself [74]. Since the nature of Raman spectroscopy is that of scattering, it can be viewed
as a “reflection” modality. Consequently, with confocal Raman spectroscopy the unwanted
influence of the matrix can be avoided. Raman measurements can be performed directly on the
bone sample, with no absolute necessity of an embedding the sample in the matrix material like
PMMA. While most bone tissue samples are likely to be found embedded in PMMA, due to crosscompatibility with histomorphometrical study, this is purely optional from a Raman spectroscopic
perspective.
Raman spectroscopy allows for the ability to gleam additional characteristics from tissue
samples, aside from identifying differences between healthy bone and ROD bone tissue. The
various bone quality indicators used for ROD diagnosis and general bone quality can be visualized
with Raman spectroscopy techniques. Such ratios include main compositional parametric ratios,
mineral-to-matrix and carbonate-to-amide I, and important constituents including calcium and
phenylalanine. Not only can several distinct ratios and constituents be obtained with clarity, but
statistical analysis can be conducted with extraordinary accuracy due to being performed upon
hundreds of thousands of Raman spectra. Previous Raman spectroscopy literature has barely
touched upon this approach, having a preference of using bright-field microscopy or FTIR image
overlays as the visual representation of the sample [71], [72], [74]–[79]. This provides a valuable
scenario for Raman spectroscopy: the combination of experimental findings, applied imagereconstruction technology, and suitable statistical analysis that paves way for the development of
an incredible foundation to tackle bone quality investigations of the future.
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Chapter 2: Methodology

2.1 CLASSICAL DESCRIPTION OF RAMAN SPECTROSCOPY
Consider a molecule that does not have a permanent dipole moment, containing a
positively charged nucleus surrounded by negatively charged electrons. Electromagnetic
radiation interacts with the molecule, inducing an oscillating electric field. The electric field can
be described as:
𝐸 = 𝐸0 cos(𝜔𝑡) = 𝐸0 cos(2𝜋𝑣0 𝑡)
Equation 2.1: Electric field induced by electromagnetic radiation

Where 𝐸0 is the maximum amplitude of the electric field, 𝑣0 is the frequency of the electric field,
and 𝑡 is the time of the electromagnetic radiation interaction with the molecule. The electric field
will induce a dipole moment in the molecule:
𝜇 = 𝛼𝐸 = 𝛼𝐸0 cos(𝜔𝐿 𝑡)
Equation 2.2: Electric field induced dipole moment
Where µ is the dipole moment, α is the polarization of the molecule, E0 is the
maximum amplitude of the electric field with a dependence on frequency ωL. Molecules
exhibiting asymmetry geometry cause the dipole moment µ to no longer be parallel with
the electric field E. As such, α is the polarizability tensor of the molecule. The components
of the dipole moment µ due to the polarizability tensor α can be written:
𝛼𝑥𝑥
𝑃𝑥
[𝑃𝑦 ] =  [𝛼𝑦𝑥
𝛼𝑧𝑥
𝑃𝑧

𝛼𝑥𝑦
𝛼𝑦𝑦
𝛼𝑧𝑦

𝛼𝑥𝑧 𝐸𝑥
𝛼𝑦𝑧 ] [𝐸𝑦 ]
𝛼𝑧𝑧 𝐸𝑧

Equation 2.3: Polarizability tensor dipole moment components
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The polarization of the molecule contains contributions from a molecule’s vibration.
The polarizability tensor α depends on the vibrational coordinate Q, which in return
depends on the molecular vibrational angular frequency𝜔𝑀 , as shown:
𝑄 = 𝑄0 cos(𝜔𝑀 𝑡)
Equation 2.4: Vibrational coordinate due to molecular vibrational angular frequency
Therefore, Raman frequency components can be obtained through amplitude modulation,
an event because of the change in a molecule’s polarization. The implementation of the Taylor
series expansion for the polarization allows for the greater understanding of the phenomenon:
𝛿𝛼

𝛼 =  𝛼0 + (𝛿𝑄 ) 𝑄 + …
Equation 2.5: Taylor series expansion for polarizability
Inserting the Taylor series expansion (Eq. 2.5) and the vibrational coordinate Q equation (Eq. 2.4)
into the induced dipole equation (Eq. 2.2) allows for the following first-order expression to be
obtained (Eq. 2.6) which can then be expanded (Eq. 2.7):

𝜇 = 𝛼0 𝐸0 𝑐𝑜𝑠(𝜔𝐿 𝑡) + (

𝛿𝛼
) (𝑄0 𝐸0 𝑐𝑜𝑠(𝜔𝑀 𝑡)(𝑐𝑜𝑠(𝜔𝐿 𝑡)
𝛿𝑄

Equation 2.6: First-order induced dipole moment
1
𝛿𝛼
𝜇 = 𝜶𝟎 𝑬𝟎 𝐜𝐨𝐬(𝝎𝑳 𝒕) + 𝑄0 𝐸0 ( )(𝒄𝒐𝒔((𝝎𝑳 − 𝝎𝑴 )𝒕) + 𝐜𝐨𝐬((𝝎𝑳 +  𝝎𝑴 )𝒕)
2
𝛿𝑄
Equation 2.7: Expansion of the first-order induced dipole moment
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Three components of the completed first-order induced dipole moment equation provide
observations of interest. The first term,𝜶𝟎 𝑬𝟎 𝐜𝐨𝐬(𝝎𝑳 𝒕), accounts for no changes in frequency
between the scattered light and the incident light. This describes elastic scattering of
electromagnetic radiation, known as Rayleigh scattering. The second term, 𝒄𝒐𝒔((𝝎𝑳 − 𝝎𝑴 )𝒕),
accounts for inelastic scattering where a molecule emits a photon with decreased energy from the
incident photon. This event is known as Stokes scattering. The third term, 𝐜𝐨𝐬((𝝎𝑳 + 𝝎𝑴 )𝒕 ,
accounts for the other form of inelastic scattering where the emitted photon has increased energy
instead. This event is known as anti-Stokes scattering.

2.2 QUANTUM APPROACH TOWARDS RAMAN SPECTROSCOPY
Within a material, there are a multitude of structures available – whether they are molecular
structures, lattice structures, or chemical functional groups. A scattered photon that comes in
contact with a material’s structure will interact with the structure in terms of energy transfer and
deflection. During a photon’s collision with a structure, a transfer of energy to the structure occurs.
This will excite the structure into a virtual quantum state. The structure will return to ground state
and re-emit the photon. The re-emitted photon will either have a difference in energy it had prior
to collision, or will have the same energy as prior to collision. If no changes in energy is observed,
the photon’s wavelength does not modify and elastic scattering, or Rayleigh scattering, occurs.
However, if the structure returns to its ground state and re-emits a photon with less energy than
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Figure 2.1: Energy level diagram for Raman scattering.
(a) Stokes Raman scattering (b) anti-Stokes Raman scattering [123].
before, the photon will have a change in wavelength lowering its frequency and increasing its
wavelength. This change is tiny, often within the order of a few wavenumbers (cm-1). If prior to
collision the structure has a higher energy than the photon, the structure will re-emit a photon with
higher energy, with a higher frequency. Observing the spectrum, if the emitted photon has lower
energy spectral lines, they are called Stokes spectral lines. In relation, if higher energy spectral
lines are observed, they are called Anti-Stokes lines.
2.3 SURFACE-ENHANCED RAMAN SPECTROSCOPY
Surface-enhanced Raman spectroscopy (SERS) was discovered in 1974 through the
investigation of Raman scattering enhancement observed in pyridine adsorption on soft silver
electrodes [80]. Following the initial examination of enhanced Raman spectroscopy, SERS has
gone through multiple advances in understanding and expanding the technique, arriving to the
correct interpretation of the SERS phenomenon in 1977 [81]. It was not until 1997 when singlemolecule observation through SERS was achieved, which served as a strong incentive for other
scientists, outside of electrochemistry and Raman spectroscopy expertise, to consider the SERS
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technique. It was shown that despite the Raman effect being subtle in nature, the signal strength of
SERS was able to rival the intensity of commonly used fluorescent techniques [82], [83].
The SERS enhancement factor is now known to be composed of two distinct phenomena:
electromagnetic (EM) and chemical (CM) enhancement mechanisms [84]. Electromagnetic
enhancement serves as the bulk of the enhancement factor due to local EM field effects, providing
enhancement of the order of 104–1010 [84], [85]. Chemical enhancement attributed to the metaladsorbate charge resonance and interactions has a considerably lower magnitude influence,
contributing to a factor of 102–103 [84]–[86]. The level of enhancement that can be achieved in
SERS depends on the nature of the metallic nanoparticles themselves alongside with the proximity
of the target analyte to the metallic nanoparticles. If the analyte is pseudo-trapped in the vicinity
of a metallic cavity looking like, also called Raman ‘hot-spot’, there is a higher probability of
observing significant increases in amplification of the Raman signal [40], [84], [87]. The increase
in signal amplification is so immense in these SERS-active locations, that even single-molecule
studies have been conducted: up to enhancement factors over 10 10 when individual molecules are
adhering to the metallic nanoparticles [37], [40], [41], [87]. It is important to note that due to the
nature of the metallic nanoparticles utilized in SERS, the amplification of the Raman signal is
procured through a label-free means since the Raman signal is primarily obtained from the
plasmonic properties of the metallic nanoparticles themselves.
In the context of SERS, we have three primary conditions that can influence the resulting
SERS signal. These conditions are adsorption and polarizability of the analyte, along with the
analytes orientation in respect to the metallic nanoparticles. [37], [40], [87], [88]. Under the
influence of the aforementioned conditions, rapid changes in the observed SERS spectrum can
occur. These changes show unique characteristics, modifying specific vibrational intensities to a
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rather significant degree, so much so that multiple “perspectives” of an analyte are observable.
The analyte orientation towards the metallic nanoparticles can greately affect the resulting
spectrum – the observed Raman intensities of specific vibrational lines are completely suppressed
or enhanced (the desired effect). In DA, there is no observable activity of the 750 cm-1 and 795
cm-1 vibrations that are associated with either the out-of-plane O-H and C-H bending mode, or the
in-plane phenolic ring bending mode [41], [89]. Since these Raman lines corresponds to bulk
dopamine signatures (i.e., powder of dopamine), observation of these vibrations on SERS
experimental results imply accumulation of multiple layers of dopamine. On the other hand, if
dopamine orientation to the metallic nanoparticle is optimal, a remarkable amplification of other
Raman intensities at different wavenumbers than those previously mentioned can be observed.
This can be explained by which vibrations that are usually associated with larger components of
polarizability in the direction normal to the metallic nanoparticle surface, will then become more
enhanced.
One area of concern with SERS is the increased difficulty of interpretation of such results
for more complex molecules. Simple molecules lead to only a few unique bands. Therefore, are
easy to categorize or observe. However, the complexity in bands increases exponentially with an
increased intricacy of the molecule under investigation. This leads into a slight complication, since
it becomes rather difficult to completely explain and deconstruct a molecule based on pure
experimental data. With the overlapping vibrational modes and component distribution for singular
molecular identities, strictly adhering to experimental methods can result in the derivation of
unclear observations [90]. For example, proteins exhibit up to 7 different amide components, each
amide having characteristic vibrational modes. Nevertheless, with the complimentary application
of the theoretical approach of SERS, a detailed understanding of Raman mode derivation from
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unique components can greatly improve the understanding of the obtained Raman spectra.
Theoretical studies have been conducted to tackle this aspect of SERS, and two main levels of
theories are utilized for proper SERS spectra simulations: (1) the plasmonic substrate (i.e.,
electromagnetic field enhancement) and (2) the substrate-sample chemical enhancement. Because
these two aspects of SERS enhancements are both present during analyte-metallic substrate
interaction, it is difficult for a singular, unified theory to be developed, despite many attempts for
deriving a solution [91].
2.4 COMPUTATIONAL SIMULATIONS
Despite the major hurdle of describing SERS with a unified theory being present,
computational chemical methods can be applied with a sufficiently good agreement with
experimental results to provide a respectable simulation of the SERS phenomena. With the
emergence of greater computational power and associated computational methods, it is now
possible to identify structural modifications of analytes and their influence on vibrational outcomes
in a purely theoretical setting. Application of computational quantum techniques, such as density
field theory (DFT) and hybrid functional basis sets like B3LYP and B3PW91, provides Raman
band activities that can simulate both standard Raman spectra and SERS spectra, depending if
metallic nanoparticles are co-simulated or not [92].
Results obtained through DFT calculations are generally in agreement with the
experimental Raman investigations of molecular vibrations. However, one very important feature
to note is the orientation of the sample (i.e., a molecule here) with respect to a SERS substrate.
This orientation is paramount to derivation of correct Raman modes. Many papers have been
published on this subject, with many agreeing that orientation of the molecule (within a simulated
environment) is integral for accurate results [93], [94]. However, there is a single caveat that’s
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observed in the majority of the articles tackling DFT calculations: the proper simulation of the
SERS substrate of interest. The actual creation of a SERS substrate molecule is not the hurdle, but
instead the interaction and orientation of the SERS substrate regarding the primary sample. Since
it is difficult to simulate a metallic cavity (i.e., a Raman ‘hot-spot’), a different orientation of a
silver dimer near the analyte under study should be considered. Without the molecule placed in the
‘hot-spot’ vicinity, a significant decrease in the Raman signal’s intensity will occur [37]–[40], [87],
[88]. As such, it is paramount in SERS simulations to achieve the ideal orientation between the
SERS substrate and the sample of interest.
The computational chemistry calculations were conducted using the Gaussian Analytical
Suite Module from the Texas Advanced Computing Center (TACC). We initialized all dopamine
molecules using both the Avogadro open-source software and GaussView 6 [95]. All dopamine
molecule forms: neutral (DA0), cationic (DA+), and anionic (DA−), were optimized through the
Gaussian software. Following optimization, vibrational frequency and Raman activities were
calculated utilizing the hybrid B3LYP method (Becke 3-parameter Lee-Yang-Parr correlation
functional) [96], [97]. The 6-311G(d,p) Pople split valence diffused and polarized basis set were
used for all calculations.
Raman activities, Si, obtained from the Gaussian module suite were converted into Raman
intensities, Ii, by using the following equation [98]–[100]:

𝐼𝑖 =

𝑓𝑆𝑖 (𝑣0 − 𝑣𝑖 )4
ℎ𝑐𝑣
𝑣𝑖 [1 − exp(− 𝑘𝑇 𝑖 )]

Equation 2.8: Raman intensity conversion from Raman activities
where 0 is the excitation frequency (532 nm), i is the vibrational wavenumber from the ith normal
mode, h is the Planck’s constant, c is the speed of light, and k is the Boltzmann constant. For all
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wavenumbers, a factor of f = 1e-12 was used to normalize peak intensities. A value of 293.15 Kelvin
was used for temperature, T. Lorentzian band shapes were applied to the resulting Raman spectral
lines, using a full width at half maximum (FWHM) of 7 cm-1. To enable data plotting, parsing of
the Raman output data was conducted through MATLAB r2016a.

2.5 CONFOCAL RAMAN VISUALIZATION
The visualization and imaging of confocal Raman spectra was conducted through
MATLAB r2016a. We focus the overall procedure on several steps to load and process the spectral
data to provide an in-depth reconstruction of the original scans themselves. All input files are in
the SPC file format, which is suitable not only for Raman spectra, but also for infrared and UV/VIS
spectra. Each SPC file can be considered as a database for the spectral data embedded in it.
Information such as experimental type, the instrument used for measurements, the quantity of
scans, collection time, and even the axis labels from the source instrument, are all available within
the SPC file. With the descriptive information available, combined with the raw-data containers in
the SPC file, all the information required for imaging is now present.
Processing the SPC file requires thresholds in place to prevent invalid information from
corrupting the image generation process. Based on the integrated spectrum of the SPC file,
outlying values that dwell in the noise regions or extreme photoluminescence peaks are nullified.
Each image comprises 22,500 spectra, which are reshaped into a 150 x 150 matrix that serves as
the foundation of the generated image.
Each spectrum within the matrix will have a variance associated to its intensities. The
variance can be in part due to deviation in laser focus (as per different height in a sample’s surface
features), or polarization, or the degree of photoluminescence in that point in the sample. A prime
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Figure 2.2: Single-wavenumber image generation on ROD bone
ROD bone is used here as an example of single-wavenumber image generation. Proline (a) at
850 cm-1 and amide I protein signature (b) at 1653 cm-1. Pseudo-colouring is applied based on
wavenumber intensity per-pixel location on the image.
indicator for this variance can be observed in a spectrum of the plasma line, located at the excitation
wavelength wavenumber (i.e., centered at 0 cm-1). Every spectrum will contain a distinct response
at the 0 cm-1 , which is proportionally consistent with the rest of the intensities within that
spectrum. This presents a unique opportunity to implement a modifier unique for each spectrum
in the matrix and causes the plasma line to be uniform to its neighbors. The end result prevents
data from being representative unfairly – no spectrum will be diminished nor overly enhanced due
to any potential measurement interference.
The final step prior to presenting the image visualization is an optional background
sutraction, yet application of this step leads to the generation of higher-quality images. A suitable
minimal value that is associated with sample noise is determined throughout the sample set. This
value is used as a simple flat subtraction across spectra, removing upwards to nearly 90% of
intensity data that is associated with noise information in the sample. The result is retention of
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Figure 2.3: Ratio image generation focused on the V2PO43- / amide III ratio.
V2PO43- / amide III ratio mapping for (a) control and for (b) ROD bone. V2PO43- and amide III
activity is obtained from the 430 cm-1 and 1275 cm-1 bands, respectively.
valuable information, while significantly improving the signal-to-noise (SNR) ratio. With an
improved SNR, it becomes easier to observe intensity differences within a sample, thereby
allowing pin-point accuracy for the key bioconstituents of interest.
Image generation and visualization is the final process in the algorithm procedure. It is
important to note that the image can be generated using either a single SPC file, or multiple SPC
files. If multiple files are used, they are normalized against one another as algorithm’s ability
permits, showing a faithful representation between the images. In the ROD and control bone
figures within this thesis, a ‘multiple file’ selection is chosen, permitting direct comparison of
figures to one another. The image generation function allows for single-wavenumber distinction,
which is invaluable for differentiating bioconstituents from one another. Figure 2.2 presents an
example of a single-wavenumber generation, where Figures 2.2a and 2.2b are focused on proline
signatures and on the intensities associated with amide I, respectively. In the particular case of
bone, the bone quality identifiers are more focused on constituent ratios rather than the intensities
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of these constituents. The imaging function provides another alternative to image generation,
which is the actual reconstruction and depiction of these ratios themselves. Integration under the
specific constituent bands is used for the ratio generation, rather than focusing on a singular
wavenumber. While the same colour scheme is used in both image types, the values presented in
the ratio-generated images are distinctly different from those in the single-wavenumber intensity
images. Figure 2.3 presents an example of one bone quality ratio, specifically that of 2PO43- /
amide III, which is discussed in more depth in Chapter 3.
2.6 NANOPARTICLE AND DOPAMINE SAMPLE PREPARATION
Silver nanoparticles (Ag NP) were synthesized following methodology previously
mentioned in the literature [101]. Silver nitrate (AgNO3, >99%) and Sodium borohydride (NaBH4,
>99%) reagents were obtained from Sigma-Aldritch. Citric acid trisodium salt dihydrate
(C6H5Na3O7 · 2H2O, >99%) was obtained from ACROS. First 20 mL of 1% (w/v) citrate solution
and 75 mL of ultrapure water were poured into a round bottom flask. The solution was heated at
80°C until stable. Next, 1.7 mL of 1% (w/v) AgNO3 solution was added to the main mixture, with
a quick addition of 2 mL of 0.1% (w/v) NaBH4 solution, too. The resulted solution was kept
consistent at 80°C under vigorous stirring conditions for thirty minutes and then was allowed to
cool to room temperature. The mixture was purified through washing, resuspension, and
centrifugation several times to remove the excess impurities from the organic and unreacted
impurities.
Silver nanoparticle thin-film fabrication was conducted by mixing the Ag NPs obtained as
described above with the neurotransmitter of interest, which in this case would be the dopamine
neurotransmitter. Concentrations of the neurotransmitter ranged between 10 -5 to 10-11 M. Mixed
solutions were sonicated for 20 seconds, then drop-casted on clean cover slips followed by vacuum
27

drying to prevent premature oxidation of the sample. Vacuum drying also promoted the formation
of not only dense Ag NP films, but of uniform films, too. All films were stored in vacuum based
conditions until further Raman characterizations [41].
2.7 ROD SAMPLE PREPARATION
After Institutional Review Board (IRB) approval, 10 specimens representing 5 ROD and 5
normal adult human iliac crest bone biopsies were chosen from the database at the Mayo Clinic,
in Rochester, Minnesota, and embedded, following standard procedures, in polymethyl
methacrylate (PMMA). The specimens were from patients within the age range of 67 ± 8 and had
been acquired following the rules of the Declaration of Helsinki of 1975, revised in 2008. Biopsy
specimens had been selected upon evidence of osteomalacia due to ROD (based on their previous
histomorphometry evaluations), while postmenopausal healthy women served as the normal
group. For spectroscopic analysis, three sections (5 microns thick) were cut using a Leica RM
2265 microtome (Leica Biosystems Inc., Buffalo Grove, IL, USA) from each of the PMMAembedded sections of the specimens.
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Chapter 3: Discussion and Results

3.1 DOPAMINE INVESTIGATIONS
3.1.1 Neutral Dopamine Observations
While dopamine seems to be a simple molecule on the surface, there are three fundamental
forms of the molecule that need to be considered: the DA0 (neutral), the DA- (anionic), and the
DA+ (cationic) forms. Understanding all the fundamental forms is important due to dopamine’s
transformation that occurs between these forms – an event readily observed in all electrochemical
investigations [15]–[21]. All the three fundamental dopamine forms are expected to exhibit C s
point group symmetry as predicted by group theory, with the point mass being associated with the
primary amino group (CH2NH2) [102]. This explanation is also expanded to include both planar
and non-planar species of DA’s fundamental forms, which both exhibit Raman and infrared (IR)
modes [88], [98]. In the consideration of Raman activities, the majority of polarized bands will be
associated to in-plane vibrations, with the depolarized bands associated with out-of-plane
vibrations.
The first step requires determining the standard neutral form of dopamine and obtaining
accurate Raman vibrations for this molecular form. We established the optimized molecular
structure of neutral dopamine in the Gaussian software as shown in Figure 3.1A, with the
calculated Raman vibrations in Figure 3.1B. As a reference, the experimentally obtained Raman
spectrum of neutral dopamine is presented in Figure 3.1C and was measured on solid dopamine
(in the form of pure dopamine powder). The calculated Raman spectrum was scaled by a factor of
0.98 to compensate for the force field constraints employed in the Gaussian software. Furthermore,
adding a scaling factor corrects for potential vibrational anharmonicity within the molecule [98].
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Figure 3.1: Neutral Dopamine – optimized molecule, theoretical and experimental Raman
spectra.
(A) Optimized neutral form of a molecule of dopamine as depicted in Gaussian software, with
elements colour-coded. (B) Calculated Raman spectrum obtained from optimized neutral
dopamine. (C) Experimentally measured Raman vibrations of dopamine obtained fro m
standard dopamine powder [124].
The application of scaling factors in computational chemistry software to counter force
field constraints have been used in literature before, to align quantum mechanical approaches with
real-world conditions [88], [98]. Whilst the usage of a single scaling factor has been debated as a
proper means of compensating the systematic errors in the approaches presented above, it has been
noted that this method still has its merits [103]. Scaling factors are not uncommon when working
with Raman spectra generated with Gaussian software. In previous studies this approach has been
30

evaluated in depth, with several articles devoted solely towards the understanding and assessment
of this principle [98], [104]–[107]. For this work, despite not being able to account for all potential
errors, the scaling factor is still considered applicable due to our focus on establishing an agreement
between experimental and theoretical phenomena. It is important to note that even higher
theoretical calculations with extensive conditions cannot perfectly account for real-world
experimental conditions and observations in their entirely. However, the insights brought by such
calculations provide unique perspectives that otherwise would be unavailable.
The standard Raman spectrum of neutral dopamine has been reported in literature before,
but a repetition of results is expected to be inevitable [88]. However, the repetition contributes to
both, reproducibility and cross-checking of the results. In the comparison between the theoretical
and experimental Raman spectra of dopamine, there are discrepancies of approximately 10 ± 2 cm1

(on average) between the two spectra. When compared to a non-scaled calculated spectrum, the

differences become larger on a linear scale at higher frequencies. Figure 3.2 presents the
discrepancies between non-scaled and scaled calculated spectra contrasted to the experimental
spectra. At the lower-end of wavenumbers, below 800 cm-1, the unscaled spectrum matches the
experimental spectrum rather well. However, past the 800 cm-1 threshold, the unscaled spectrum
steadily misaligns with the experimental data. Meanwhile, the application of a scaling factor leads
to only slight alignment difficulties at lower wavenumbers, but remains appreciatably correct for
the rest of the spectrum. This suggests that there is an overestimation of the force field constant
that is used in the Gaussian simulations to produce the calculated Raman spectrum. The measured
and calculated frequencies (with the scaling factor of 0.98 applied) and values of the main
vibrational nodes of interest are presented in Table 3.1, along with their vibrational assignments.
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Figure 3.2: Neutral dopamine unscaled and scaled Raman spectra.
(A) Unscaled Raman spectrum as calculated from the Gaussian software suite on neutral
Dopamine. (B) Scaled Raman spectrum using a scaling factor of 0.98 that was applied to figure
A. (C) Experimentally measured Raman spectrum of dopamine obtained from standard
dopamine powder. Vertical red lines were applied for easier visualization of wavenumber
alignment across all spectra. Note successful early alignment across all figures at lower
wavenumbers, but a significant drop-off in Figure A’s alignment for later wavenumbers.
The vibrational assignments were obtained through direct visualization with the GaussView
software, as well as from comparison with literature [100], [103], [108]–[110]. With the calculated
spectrum matching closely with the experimental, visualization of the experimental vibrations is
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Table 3.1: Theoretically calculated and experimentally measured Raman vibrations of
dopamine with their tentative assignments [124].
Calculated
(cm−1)
381
577
622
744

Measured
(cm−1)
393
593
635
750

782

795

934
961
1029

931
962

1060
1123
1156

CH wagging, ring deformation
CH in-plane ring deformation
CH wagging; aliphatic chain C–C vibrations
CH out-of-plane; ring deformation (two band
response)
CH out-of-plane; ring deformation (two band
response)
NH twisting
NH twisting; CH wagging; ring deformation
CH wagging
C–C–N stretching; CH wagging

1117
1148
1209

1294
1321

Assignment

1355

Ring breathing; CH aromatic rocking; CH twisting
Ring breathing; CH aromatic in-plane rocking; CH
twisting
Ring deformation; OH scissoring; CH twisting

1387

CH wagging; NH twisting

1466
1615
1631
1634

1285

CH twisting; NH twisting; CN stretching
OH rocking; CH aromatic rocking; weak ring
breathing; CH wagging
CO stretching

1455
1617

CH scissoring
Ring deformation, OH scissoring
NH2 scissoring
Benzene ring deformation

indeed achievable through the software. As such, the ability to take the experimental results a step
further allows for direct visualization of the representation of the measured sample.
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Figure 3.3: Dopamine – dopaminequinone redox reaction.
The redox reaction of dopamine into its quinone form, dopaminequinone. The reaction
consists of a transfer of two electrons and two protons. The optimized structural
representations of neutral dopamine and dopaminequinone are also presented and
appropriately labeled. Elements within the molecule are appropriately colour-labeled for easy
identification [124].

3.1.2 Dopaminequinone Observations
Dopamine is expected to have reduction-oxidation reactions in the presence of water, as
mentioned in previous studies [88], [110], [111]. The expected reaction is a deprotonation of
dopamine, which can result in the formation of dopaminequinone and other minor, but charged
forms that were mentioned previously (i.e., DA- and DA+). In the 10-11 M dopamine solution that
was prepared for the experimental portion of this study, exposure of dopamine to water molecules
is very likely to occur. This anticipated activity is schematically represented in Figure 3.3 together
with the molecular representations of the initial and final molecular forms in the redox reaction.
We consider the quinone form of dopamine first due to the observable symmetry of the O-H and
N-H bonds in the dopamine molecule. From the one-step redox reaction that occurs, with two
electrons and two protons, the quinone form achieves an increased priority of focus for this
reaction. The other two forms of dopamine, the anionic and cationic structures, are not neglected
and will be further investigated in this study.
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Figure 3.4: Dopaminequinone and neutral dopamine in silver dimer proximity.
Energetically optimized dopaminequinone (A) and neutral dopamine (B) structures in the
proximity of a silver dimer. (C) From top to bottom: Simulated Raman spectrum obtained
from Gaussian computation of dopaminequinone; Experimentally obtained Raman
vibrational spectrum of dopaminequinone. (D) Simulated Raman spectrum of neutral
dopamine obtained in proximity of silver [124].
To investigate the neutral form of dopamine and dopaminequinone further, logical
progression dictates the evaluation of the theoretical and experimental Raman spectra of these
molecules in the vicinity of a SERS environment. Both of these evaluations are presented in Figure
3.4A-D. The optimized structural representations were obtained through energy optimization with
the LanL2DZ basic set, which takes into consideration the pseudopotentials for metal atoms as
shown in figures 3.4A and 3.4B. The experimental and simulated Raman spectra of both molecules
are presented in Figure 3.4C. A comparison of these two spectra shows a good agreement between
the results. It also shows a characteristic difference in the comparison with the standard dopamine
35

spectrum. In both experimental and simulated spectra shown in Figure 3.4C, there is an absence
of the 750 cm-1 and 795 cm-1 vibrations, which are both primary signatures of standard dopamine,
but should not be present in SERS experimental data, as previously discussed. These vibrations
are seen in Figure 3.4D, where the simulated Raman spectrum of neutral dopamine in the presence
of a silver dimer is presented. In fact, the 750 cm-1 and 795 cm-1 vibrations are the most intense
vibrations observable in the spectrum, alongside the 550 cm-1 and 580 cm-1 vibrations. A stronger
interaction between the silver and the dopaminequinone may be attributed to the exposure and
increased electronegativity of the oxygen atoms, which are significantly different in the neutral
dopamine. The predominant interaction between the silver dimer and the dopaminequinone can be
attributed to the dominant Raman vibrations around the 1360 cm-1 and 1510 cm-1 wavenumbers.

3.1.3 Anionic and Cationic Dopamine Observations
The redox reactions of dopamine in water is expected to result in the disassociation of
neutral dopamine into its anionic and cationic forms. The sample preparation of dopamine exposes
it to both air and water, therefore consideration for the two ionic forms of dopamine are warranted.
Both ionic forms were theoretically optimized prior to having their Raman spectra calculated, with
and without the presence of a silver dimer. The anionic and cationic structures and Raman spectra
are presented in Figures 3.5A-D and Figures 3.6A-D, respectively. The slightly volatile forms
induce deformations of the amine chains, which is manifested by the torsional and bending of these
chains. These deformations are visible in the structural representations in Figures 3.5A,B and
Figures 3.6A,B. Further observations concern the silver dimer, which exhibits unique orientations
depending on the ionic form of the dopamine molecule. In the anionic form, the silver dimer
presents a planar orientation with respect to the benzene ring and it is asymmetrically closer to the
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Figure 3.5: Anionic dopamine within and without silver dimer proximity.
Energetically optimized anionic form of dopamine without silver (A) and within the
proximity of a silver dimer (B). (C) Simulated Raman spectrum obtained from Gaussian
computation of anionic dopamine. (D) Simulated Raman spectrum of anionic dopamine
obtained in proximity of silver, and experimentally obtained Raman spectrum of anionic
dopamine in silver SERS substrate [124].
unshielded oxygen atom. In the cationic form, a quasi-planar position of the silver dimer is
adopted, facing towards the ammonium NH3+ functional group.
The two ionic forms present differences in the characteristic Raman vibrational
frequencies, as seen in Figures 3.5C and 3.6C for the anionic and the cationic forms, respectively.
The dominant peaks are listed as follows: the anionic form shows dominant peaks at 640, 750,
780, 930, 1150, 1280, 1530, and 1610 cm-1, with the cationic form showing dominant peaks at
580, 800, 820, 1180, 1330, 1390, 1480, and 1640 cm-1. Exposure to the silver dimer presents
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Figure 3.6: Cationic dopamine within and without silver dimer proximity.
Energetically optimized cationic form of dopamine without silver (A) and within the proximity
of a silver dimer (B). (C) Simulated Raman spectrum obtained from Gaussian computation of
cationic dopamine. (D) Simulated Raman spectrum of cationic dopamine obtained in the
proximity of silver [124].
modifications to various Raman vibrations, resulting in the Raman spectra presented in Figures
3.5D and 3.6D for the anionic and the cationic forms of dopamine, respectively. It is interesting to
note the decrease in the intensities of the 750 cm-1 and 780 cm-1 lines for the anionic form. These
intensities appear to be roughly a ‘middle-ground’ between those of neutral dopamine and of
dopaminequinone. The opposite behavior is observed in the cationic form, where an increase in
the two Raman vibrations is observed. This change in intensity is similar to that seen for the neutral
dopamine in the presence of the silver dimer. Besides these two prominent vibrational lines, we
also observe variances in other frequencies, where both, intensities and positions are varying. An
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experimentally obtained Raman spectrum for the anionic dopamine is presented in Figure 3.5D for
an easier comparative analysis. A vertical translation has been applied for easier visual acuity.
With the dopamine anion, there is a strong and interesting Raman line at 1150 cm-1. This
peak, which has been previously measured [15], [88], seems to originate from the in-plane bending
of the anionic dopamine as visualized with the Gaussian vibrational mode simulation. The
detection of this peak, which is only observable in the anionic form of dopamine, supports the
assumption that the anion form may be present in aqueous solutions. It is important to note that
the drying process in the sample preparation does not support a pure water-absent conclusion, as
such, some water molecules may remain attached to the dopamine ions. The interaction between
the water molecules and the dopamine ions may induce screening and hindrance of charge
neutralization. The screening effect in particular can be rather strong due to its proportionality to
the high dielectric constant of water (i.e., ε = 80). Another factor that may preserve the ionic signal
is the development of image charges, an effect arising from the proximity of the analyte to the
metallic silver nanoparticles; a decrease of Born energy inferior to the dissociation entropy energy
of the charges. Therefore, when the value of entropy is sufficiently large, the dopamine molecules
retain their charged state and present a dynamic equilibrium between the cationic and anionic
forms. Furthermore, the thermal energy obtained from the laser excitation used in Raman
spectroscopy may be a contributing factor as well.
3.1.4 Zwitterion Dopamine Observations
Charge redistribution and intramolecular hydrogen bond formation may occur within a
dopamine molecule. We present an example of this event in Figure 3.7A, where an uncharged
dopamine zwitterion is in the proximity of a silver dimer. The theoretical and experimental Raman
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Figure 3.7: Dopamine zwitterion within silver-dimer proximity.
(A) Dopamine zwitterion (DA±) optimized in the proximity of silver. (B) Theoretical and
experimentally measured Raman vibrations are presented and labeled. Vertical translation
provided for easier visualization and comparative quantification [124].
spectra of the phenomenon is presented in Figure 3.7B. A cursory glance reveals an appreciable
bending of the amine chain towards the silver dimer, with the silver dimer’s orientation being
quasi-perpendicular to the benzene ring. The energetically optimized structure suggests that this
form of dopamine could interact with the silver surface through both functional groups: the
electronegative oxygen and the electropositive amine chain. As for the characteristic dopamine
vibrations of around 750 cm-1 and 790 cm-1, not only did the SERS cases of dopaminequinone and
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anionic dopamine show diminished vibrations in this frequency region, but also the zwitterionic
form, which exhibits an attenuation of these prominent vibrations.

3.1.5 Dopamine Electrochemical Observations
Figure 3.7B also shows a good agreement between the calculated and measured results,
which not only confirms the existence of the theoretical structure in experimental solution but also
provides an insight of distinct morphological changes that may occur to dopamine. Considering
the solute environment and other analyte detection techniques, such as fast-scan cyclic
voltammetry, dopamine may undergo many distinct structural and electrochemical changes. These
modifications would result in different observations than just for the pure neutral dopamine. The
current results suggest two potential dopamine forms that may arise during electrochemical
analytical processes. The first form would correspond to the oxidation state of dopamine, with the
dopaminequinone being the most likely predominant form detected. For the reduced form of
dopamine, which is created when the potential is applied in the negative direction, the zwitterionic
form of dopamine is the most likely predominant analyte form. Furthermore, in the presence of a
silver surface, reorientation and deformation of dopamine is highly probable to occur, depending
on the charged form of dopamine present. We observe a quasi-planar orientation with respect to
the oxygen atoms in the dopaminequinone, with a drastically bent amine chain (and oxygen
adsorption) in the zwitterionic form.
Each unique dopamine configuration, from the dopaminequinone to the anionic form or to
the zwitterionic form, contains characteristic dopamine signatures. Examples of these signatures
are: for dopaminequinone at 950 cm-1 and 1360 cm-1, for the anionic form around 1160, 1290, and
1530 cm-1, and for the zwitterionic form around 1280 cm-1 and 1640 cm-1. To control for potential
fluctuations during experimental data acquisition, and to control the probability of the
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Figure 3.8: Dopamine overall-average of SERS spectra.
Overall average of 400 SERS spectra, recorded in eight distinct locations on the sample. Each
location was measured through time series acquisitions of 50 SERS spectra each, at 200
milliseconds per spectra [124].
characteristics of each dopamine configuration, we present in Figure 3.8 an average of 400 SERS
spectra. We collected these spectra in several locations on the sample; eight distinct locations with
fifty SERS time series spectra each, at 200 milliseconds per spectra. With the intensities of the
wavenumbers as an indicator, the dopaminequinone form appears to be the predominant
configuration observed within the experimental data. The anionic and zwitterionic form are next,
with potentially the same occurrence for both. One important feature to note is the absence of the
750 cm-1 and 790 cm-1 dopamine signatures, which is a characteristic indicator of neutral dopamine
(as seen in the standard dopamine powder measured in Figure 3.1). If the occurrence of these
signatures is observed, it would indicate either neutral dopamine itself existence (likely in a multilayer format), or that of the cationic form.
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3.2 RENAL OSTEODYSTROPHY INVESTIGATIONS
3.2.1 Control and ROD Bioconstituent Analysis
In tackling renal osteodystrophy, a distinctly different approach must be taken compared
to the approach used for investigating dopamine. The analysis and observation of several
bioconstituents must be simultaneously undertaken, with high fidelity, for the appropriate
diagnosis of ROD to take place. Raman spectroscopy does allow for such analysis to take place,
as shown in Figure 3.9 where an integrated spectra overview of all observable bioconstituents
within ROD and healthy (control) bone tissue is presented. A cursory look reveals distinct
differences of phenylalanine vibrational intensities at 1005 cm-1 and 1609 cm-1 between the two
tissue samples. The relatively higher vibration intensity in the ROD sample corresponds with a
larger presence of phenylalanine, which is expected to occur due to the physiological changes that
accompany ROD. With a malfunctioning kidney and with or without a malfunctioning liver,
increase quantities of phenylalanine can be expected, together with the decrease of tyrosine [112].
Focusing on the physiological changes that take place over the course of ROD, the phenylalanine
hydroxylase (PAH) enzyme is impaired due to the diseased kidney’s failure to express the enzyme
properly. PAH’s key role is the conversion of phenylalanine that is obtained from diet into tyrosine
through the hydroxylation of phenylalanine’s aromatic side chain. Due to improper function of the
kidney, the hydroxylation event is unable to proceed, leading to phenylalanine accumulation, as
viewed in the ROD spectrum presented in Figure 3.9.
The means in which Figure 3.9 was generated is important, due to the statistical
significance that can be derived from it. The Raman spectra were obtained by averaging the
integrated image spectra acquired from different locations within the bone tissue samples. Each
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Figure 3.9: Integrated Raman spectra of ROD and control bone.
Each spectrum was obtained through averaging hundreds of thousands independent spectra
from their respective tissue samples. ROD spectrum is vertically offset for easier comparison
between the two integrated spectra [125].zz
integrated image spectrum is reconstructed from 22,500 Raman spectra that were obtained during
confocal Raman mapping measurements. Multiple different integrated images were averaged
together to create the overall average spectra presented in Figure 3.9. Thus, the procedure requires
averaging hundreds of thousands of spectra to formulate the final outcomes, portraying a strong
and accurate presentation of the bioconstituents and the BTM of the two bone samples. Whilst the
laser raster technique employed during the measurements necessitates several minutes for
completion, an unprecedented degree of accuracy is presented within these results. This is
especially important when observing the notable accumulation of the phenylalanine in the ROD
samples – the first time such a distinction has been noted with Raman spectroscopy, to the best of
our knowledge.
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Further analysis of the integrated spectra in Figure 3.9 reveals other several expected
bioconstituents of bone structural framework. For example, the four vibrational lines at 964, 440,
1040, and 595 cm-1 are associated with phosphate vibrational modes. Carbonate presence can be
observed from the 1075 cm-1 line and proline from the 863 cm-1 line. The two most prominent
protein signatures are at 1650 cm-1 and 1275 cm-1, corresponding to amide I and III, respectively.
Although these components have been previously detected and reported in the literature, one
notable difference in the spectra presented here is the concentration of phenylalanine – a variance
that was expected to occur in the ROD sample. No other noticeable differences in these vibrational
band intensities can be perceived.

3.2.2 Phenylalanine as a Biomarker
Since phenylalanine presents itself as a potential biomarker for the disease, it may be
viewed as a prospective ROD signature. Thus, further analysis was conducted on the phenylalanine
vibrations and is presented in Figure 3.10a-d. Both the control bone and ROD bone samples are
visualized for the 1005 cm-1 and 1609 cm-1 signatures through confocal Raman imaging. Pseudocolouring was applied in these images at the particular vibration’s wavenumber, for contrast and
easy distinction between vibrational intensities within the images. The colour yellow corresponds
to the highest Raman vibrational activity and dark blue to the lowest Raman vibrational activity.
All images underwent background subtraction and normalization. The colour bars to the right of
each image show such normalization of the intensity. Interpretation of the images reveals two
distinct aspects of phenylalanine activity within the bone tissues. Both the control (Figure 3.10a,c)
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Figure 3.10: Confocal Raman mapping focused on phenylalanine activity.
Phenylalanine 1005 cm-1 (a,b) and 1609 cm-1 (c,d) vibrational line visualization is shown in
control and ROD respectively. Pseudo colouring is applied to differentiate intensity of activity,
where dark blue indicates minimal activity and bright yellow indicates maximum activity
observed [125].
and ROD (Figure 3.10b,d) shows agreement of vibrational line location at 1005 cm-1 and 1609 cm1

. This observation, in part, acts as confirmation that both vibrations are associated with the same

bioconstituent, which is phenylalanine in this case. Figure 3.10a,c reveals an acceptable
distribution of phenylalanine throughout the bone tissue, with a low intensity, which indicates an
acceptable phenylalanine concentration. Figure 3.10b,d reveals a different behaviour all together.
Not only does the phenylalanine nearly encompasses the whole scanning region, but its intensity
is also distinctly increased in comparison with the control sample. Considering that the intensity
of the phenylalanine is reflective to its concentration, the ROD bone contains a greater amount of
phenylalanine as compared to the control.
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3.2.3 Calcium Content Biomarker
A known factor in patients with progressive ROD is a combination of high serum
phosphate levels and low serum calcium levels. These levels are attributed to a damaged kidney
function and serve as two BTM used in clinical detection. As described previously, the kidney is
unable to properly excrete phosphate leading to excessive phosphate accumulation within the
body’s circulation system. This excess of phosphate binds with calcium, drastically lowering the
body’s circulatory calcium concentration. With the kidney’s being unable to convert vitamin D3
to calcitriol, the body is no longer capable to absorb calcium from the gut. The kidney’s ability to
reabsorb calcium is severely dilapidated. This leads to a systematic resorption of the body’s
skeletal system due to being the only available calcium reservoir left accessible. The calcium levels
within the skeletal system will continually decrease, until fracture events will naturally be
occurring; there are no longer any means for the skeletal system to undergo bone formation.
Considering the series of physiological events that accompany kidney failure and ROD
progression, the bone turnover is thereby affected. These events are usually analysed by focusing
on the calcium levels in the normal and ROD bone samples, as seen in Figure 3.11a,b, respectively.
Calcium content can be indirectly quantified by observing the 2PO43- / amide III ratio, as reported
by Roschger et al [113]. This ratio corresponds to the area under the Raman band from 395 cm-1
to 469 cm-1 to that under the Raman band from 1215 cm-1 to 1332 cm-1 (see Figure 3.9 as
reference). These resulting figures support Roschger et al’s comments that the ratio can indirectly
characterize calcium. For example, the quantification of these band intensities in Figures 3.11a
and 3.11b, shows that Figure 3.11b has a markedly lower amount than the one observed in Figure
3.11a, providing a visual confirmation of this content in ROD bone and normal bone. Figure 3.11c
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Figure 3.11: Confocal Raman mapping focused on the 2PO43- / amide III ratio.
2PO43- / amide III ratio mapping for (a) control and for (b) ROD bone. The 2PO43- and amide
III activity is obtained from the 430 cm-1 and 1275 cm-1 bands, respectively. The ratio mapped
is an indirect quantifier of calcium content within bone tissue. (c) Histogram associated with
the 2PO43- / amide III ratios in images (a) and (b) [125].
provides a statistical analysis to assist in further quantifying the differences between the two
samples regarding the 2PO43- / amide III ratio.
The analysis presented in Figure 3.11c describes a breakdown of ratio quantification
between the two samples. This statistical analysis was performed by employing an unpaired t-test,
where the probability p is calculated to determine if both samples will have the same average
values, µ. The t-test is conducted without the assumption of the populations containing equal
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variances, and is executed through Welch’s t-test in subroutine t-test-2, MATLAB r2016a [114].
The average values derived from the histogram in Figure 3.11c, assuming a normal distribution is
in effect, leads to µa = 0.5358, σa = 0.0474, µb = 0.5042, and σb = 0.0456 for the control and ROD,
respectively. The differences of the averages result in Δ = µa − µb = 0.0316, with a 95% confidence
interval of 0.0308 < Δ < 0.0325. The probability p with which the values are sampled from the
same distribution in the average ratios for both samples will be identical and is extremely small
with a p value of under 10-300.
Considering the significant amount of spectra presented in Figure 3.11a,b, the question is
begged regarding how many scans are required for a sufficient discrimination between the two
samples. The quantity of spectra required to be measured per sample to have a detection power β
at a statistical significance level α is [114]:

𝑛𝑎 = 𝑛𝑏 = 

(𝜎𝑎2 + 𝜎𝑏2 ) (𝑍1−𝛼 + 𝑍1−𝛽 )

2

2

Δ2

Equation 3.1: Quantity of spectra required to be measured in a sample based on detection power
(β) and statistical significance level (α)
where 𝜎𝑎 and 𝜎𝑏 are the standard deviation for both samples, Z is the standard normal distribution,
and Δ = 𝜇𝑎 − 𝜇𝑏 correspond to the differences between the averages of the samples. The detection
power analysis yielded interesting results, as follows: for a detection power of 𝛽 = 90% at the
statistical significance level 𝛼 = 0.05, a value of 𝑛 = 46 is procured. This indicates that
approximately 46 recorded spectra are required per sample to have a sufficient basis to discriminate
between the sample based just on the calcium content.
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3.2.4 Mineral / Organic Content Biomarker
A different ratio that can characterize bone quality is the measurement of mineral to organic
content within the bone: the mineral-to-matrix ratio [71]–[73]. This ratio is focused on the
phosphate peak region (907 cm-1 to 990 cm-1) to that of the amide I band (1625 cm-1 to 1725 cm1

). The ratio of areas were favoured over the ratio of intensities, to minimize potential calculation

errors when comparing bone quality ratios [71]–[73], [113], [115], [116]. When the integrated
area under the two regions is analysed, the data represents the amount of mineral compared to that
of collagen, in respect to the volume presented [71]–[73]. While investigations into bone quality
ratios have been successfully conducted previously, we present here a direct visualization through
the mapping of these ratios onto the samples themselves, as shown in Figure 3.12a,b. A potential
complication with the visualization process is that some constituents, such as collagen fibres and
phosphate particles, exhibit increased polarization-sensitive characteristics under confocal Raman
microscopy [115]–[117]. Depending on the orientation of the constituents, their appearance may
either appear dark or bright, following the application of confocal Raman microscopy [115]. We
circumvent this complication using unpolarized recording of the sample with a low numerical
aperture objective (20x objective, 0.4 numerical aperture). This modality avoids the influence of
the polarization-sensitive constituents. Furthermore, as a side-effect of unpolarized recording the
sample roughness was also jointly decreased.
The data visualization in Figure 3.12a,b reveals distinctly smaller amounts of the mineralto-matrix ratio in ROD bone (Figure 3.12b) in comparison to that of the normal group (Figure
3.12a). This remark consists primarily of a fewer high-intensity yellow regions in the ROD sample
compared to the normal sample. Considering the increased bone resorption and turnover occurring
in ROD, the visible decrease in the mineral-to-matrix ratios is expected to occur. This observation
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Figure 3.12: Confocal Raman mapping focused on the phosphate / amide I ratio.
Phosphate / amide I ratio mapping for (a) control and for (b) ROD bone. Phosphate and amide
I activity is obtained from the 960 cm-1 and 1660 cm-1 bands, respectively. The ratio mapped
is associated to the mineral-to-matrix content within bone tissue. (c) Statistical analysis
associated with the phosphate / amide I ratios in images (a) and (b) [125].
is presented in Figure 3.12b. The corresponding histogram for the two samples is shown in Figure
3.12c. According to Figure 3.11c, the averages and standard deviation of the ratios are 𝜇𝑎 =
1.1876, 𝜎𝑎 = 0.143, 𝜇𝑏 = 1.0316, and 𝜎𝑏 = 0.145. The differences of these averages, Δ =  𝜇𝑎 −
𝜇𝑏 , leads to a value 0.156 with the corresponding 95% confidence interval of 0.1534 < Δ <
0.1587. Once again, the p-value obtained is negligently low, with a value less than 10 -300. Power
analysis, using the equation initially presented under Figure 3.11, shows that employing a power
of 𝛽 = 90% with confidence 𝛼 = 0.05, approximately 𝑛 = 18 recorded spectra per sample are
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required to properly distinguish between the two samples based on the phosphate / amide I ratio.
Not only is distinction even greater as per the results discussed above, but Figure 3.12c’s histogram
presents another intriguing aspect to the human condition. The ROD histograms have a nonGaussian shape, which is different than that of the control. It has a distribution skewed to the lower
side. This particular characteristic has been previously observed and commented in the literature,
having been attributed to a decrease in mineral properties and bone heterogeneity typically
associated with age [71].

3.2.5 Bone Turnover / Remodeling Activity Biomarker
Bone turnover and remodeling activity are two important assessment characteristics in
diagnosing ROD. Following a logical assessment, the carbonate-to-matrix ratio is another great
indicator that covers the two aforementioned assessments of bone quality, and it is presented in
Figure 3.13a,b. Integration of the carbonate band (from 1033 cm-1 to 1135 cm-1) and amide I band
(from 1625 cm-1 to 1725 cm-1) were utilized to develop the carbonate-to-matrix ratio [117]–[119].
Upon successful visualization of this ratio, there can be observed a noticeable decreased of the
carbonate-to-matrix ratio in the ROD image – consistent with the biological activity of high
turnover in bone. Furthermore, this decreased ratio supports the similar trend shown in Figure
3.12b, where a similar decreased in bone quality ratio for ROD when compared to that of normal
bone sample is seen. Histogram analysis is presented in Figure 3.13c and contains an average and
a deviation of 𝜇𝑎 = 1.2023, 𝜎𝑎 = 0.0952, 𝜇𝑏 = 1.1007 and 𝜎𝑏 = 0.1016. The differences of
these averages result in a Δ =  𝜇𝑎 −  𝜇𝑏 = 0.1015 with the 95% confidence interval of 0.0997 <
Δ < 0.1033 with a p-value that is once again negligible (𝑝 < 10−300 ). Using the same parameters
as in the previous power analysis, 𝛽 = 90%and 𝛼 = 0.05, a value of 𝑛 = 20 is obtained in this
case. The low number of spectra needed to differentiate the samples is another advantage. It is also
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Figure 3.13: Confocal Raman mapping focused on the carbonate / amide I ratio.
Carbonate / amide I ratio mapping for (a) control and for (b) ROD bone. Carbonate and amide
I activity is obtained from the 1074 cm-1 and 1660 cm-1 bands, respectively. The ratio mapped
is associated to the carbonate-to-matrix content within bone tissue, which is representative of
bone remodelling and turnover. (c) Statistical analysis associated with the phosphate / amide I
ratios in images (a) and (b) [125].
very similar to the value obtained for the mineral-to-matrix ratio, of 𝑛 = 18. A summary of all the
computationally estimated ratios of the analysed biomarkers, together with the number of spectra
required to accurately assess the biomarkers based on the criteria used, is summarized in Table
3.2.
The two biomarkers that are the strongest assessors of bone mechanical properties are the
mineral-to-matrix and the carbonate-to-matrix ratios. This is important towards the clinical
perspective, as it is not only difficult to determine the cause of fractures purely through
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Table 3.2: Computationally determined values of the ratios of biomarkers of interest and the
number of spectra sufﬁcient to distinguish between samples for typical statistics power of β =
90% and α = 0.05 [125].
Normal
Ratio

ROD

Average Standard Average Standard 𝚫 =  𝛍𝐚 − 𝝁𝒃
Value Deviation Value Deviation
𝝁𝒂
𝝈𝒂
𝝁𝒃
𝝁𝒃

ν2 PO3−
4 / amide III
0.5358
(associated with calcium
content)

𝒏

0.0474

0.5042

0.0456

0.0316
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ν2 PO3−
4 / amide I
(mineral-to-matrix)

1.1876

0.143

1.0316

0.145

0.156

18

ν2 CO2−
3 / amide I
(carbonate-to-matrix)

1.2023

0.0952

1.1007

0.1015

0.1015

20

histomorphometry analysis, but doing it noninvasively is difficult [50]. The mapping
visualizations presented here are, to the best of our knowledge, the first time to have ever occurred
in tackling ROD with Raman spectroscopy. These visualizations provide a spatial insight in the
distribution and intensity of all these biomarkers within the bone, and can be used in future
diagnostic techniques when monitoring ROD signatures.
Each of the samples recorded contains 22,500 (150 x 150) confocal Raman spectra with
uniform normalization and background subtraction applied to decrease any potential signal-tonoise ratio complications. Combined with the mapping of three potent biomarkers: the calcium
content (Figure 3.12a,b), the mineral-to-matrix ratio (Figure 3.13a,b), and the carbonate-to-matrix
ratio (Figure 3.14a,b), a clear distinction between ROD and normal bone is achieved.
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Chapter 4: Conclusions
4.1 DOPAMINE CONCLUDING REMARKS
The first part of this study concludes theoretical and experimental approaches towards the
detection of dopamine at concentrations of 10 -11 molar. Not only was the detection successful, but
the concentrations used here were significantly lower than in vivo conditions, where extracellular
dopamine levels can exist between 10 nM to as high as hundreds of micromoles, or even in the
millimolar range [120]–[122]. Although the measurements conducted were not performed in an
aqueous solution, they provide a valuable understanding of the vibrational assignments observed.
The absence of aqueous media provides two advantages: the broadening of Raman bands
characteristic to liquid media is eliminated, and the computational overhead is reduced and
simplified.
A greater challenge to the one that was conducted here would be the reproducibility of
Raman intensities within a liquid environment. In the scenario of low concentrations, the
probability of dopamine aggregation would need special attention. Localized regions of particles
can develop into intense optical fields as per involvement from adjacent plasmonic surfaces. This
can lead to SERS enhancement of their inherently weak Raman signals. Through eliminating the
limitation of an aqueous solution environment, but still preserving the desired neurotransmitter
concentration, we are able to obtain important insights into the nature of dopamine detection –
especially its complexity at very low concentrations.
The measurements and analytics conducted by the theoretical and experimental methods
presented in this study show a relatively good agreement with one another. This suggests the
possibility that the dopamine molecule is not always in its pure, neutral state. Instead, different
forms of dopamine, such as the zwitterionic, anionic, and dopaminequinone, are all present. These
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forms of dopamine in the proximity of a SERS environment lose the dominant dopamine
characteristic vibrations at 750 cm-1 and 790 cm-1. This is highly suggestive of their adsorption to
the metallic nanoparticles under various orientations. On another note, if the occurrence of the
abovementioned characteristic vibrations is observed, it would imply the potential presence of
neutral dopamine in a multilayer form or that of cation dopamine ions. When observing dopamine
measurements from a redox reaction perspective, an event that occurs during electrochemical
measurements, two dominant forms of dopamine are expected. During the oxidation process, the
dopaminequinone is more likely to be detected while the zwitterionic form is likely to occur during
the reduction phase.
Considering the ultrasensitive aspect of the current experimental data, combined with the
theoretical analysis presented in this work, valuable insight may be gleamed towards the
advancement of dopamine monitoring and detection, and future applications thereof.
4.2 RENAL OSTEODYSTROPHY CONCLUDING REMARKS
The second portion of this study focuses on finding alternative methods for ROD detection.
We have combined three different techniques towards this pursuit: confocal Raman spectroscopy,
spectroscopic visualization with signal processing methods, and statistical analysis. This
combination revealed differences in bone composition (i.e., between healthy bone samples that
acts as the control, and ROD bone tissues) for the characteristic biomarkers with a fantastic
accuracy. In focusing on ROD specific biomarkers, we achieved direct visualization of calcium
content, mineral-to-matrix ratio, and carbonate-to-matrix ratios, including their respective ratio
specifications. Visualization and statistical analysis confirm substantially lower values in ROD
samples than those seen in healthy, control bone.
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Not only was detection and visualization of these ratios achieved, but phenylalanine was
successfully measured and analyzed with Raman spectroscopy for the first time to our knowledge.
Detection of this analyte is paramount in ROD diagnosis due to its substantial role. Indeed, one
could even note that future diagnostic studies focused specifically on phenylalanine may be
developed, as this analyte could be an early indicator of the disease itself. Supporting argument is
that during chronic kidney disease, phenylalanine can no longer be converted into tyrosine, leading
to a substantial increase in systematic phenylalanine concentration. If this complication occurs, the
body’s regulatory system will systematically undergo bone resorption leading to the development
of ROD, as presented here.
Each image presented in this study was reconstructed from over 22,500 spectra per sample.
The sheer quantity of spectra leads to statistically different average ratios between normal and
ROD bone as well as providing a rather powerful method for distinguishing between the two
samples. With the analysis presented here, the statistic power requires relatively few samples to
successfully differentiate ROD from normal bone based on matrix ratios – approximately twenty
samples in total. This raises a potential framework for future in vivo Raman measurements as
sample data acquisition can be realistically conducted through the use of fiber-optic-based Raman
sensors.
Whilst the development of fiber-optic-based Raman sensors is currently out of scope for
this project, the research conducted here contributes towards this goal of achieving in vivo,
minimally invasive Raman diagnosis. Through the application of a visualization algorithmic
approach, combined with statistical analysis, the nascent steps towards a ROD detection baseline
have been achieved.
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